Mannkind
As of the edition of 20 October 2026, Mannkind runs 9 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- scPharmaceuticals, Inc.: acquired in 2025; successor Mannkind Corporation
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Status not established | 3 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Insulin human | Ended 1994 (computed from the first US licence) | 1 |
| Furosemide | none listed | 2 |
A route B row is one company at one target.
Where its trials are
- Cancer: 3 trials led
- Hormones: 3 trials led
- Nutrition and metabolism: 3 trials led